Animal models in molecular biology research: Challenges, ethical imperatives, and the path to human-relevant translation

Abstract

Experimental animal models have historically been pivotal in molecular biology, providing insights into gene function, disease causes, and therapeutic advancements. However, their translational relevance is increasingly scrutinized due to interspecies variations, ethical dilemmas, and restricted reproducibility. The objective of this study is to critically analyze the obstacles and ethical considerations related to animal models in molecular biology, while highlighting the promise of human-relevant and combinatorial techniques to enhance translational outcomes. A narrative synthesis of literature published from 2013 to 2025 was performed via PubMed, Scopus, Web of Science, and Google Scholar. Research focusing on model development, translational obstacles, ethical implications, and disease-specific applications—encompassing neurodegenerative, metabolic, oncological, hepatic, renal, and pain models—was prioritized. Animal models are indispensable but insufficient for precisely mirroring human disease. Principal challenges include species variability, infrastructural limitations, and insufficient reproducibility. Innovative approaches such as humanized models, organoids, and CRISPR/Cas9 technologies, when combined with rigorous methodologies, controlled heterogeneity, and ethical safeguards, offer a means to improve the predictability and reliability of preclinical research. Progress in molecular biology needs to include strict planning, long-lasting infrastructure, and new ideas from interdisciplinary fields. Integrating human-relevant and combinatorial approaches can improve the scientific integrity and ethical underpinning of biomedical research.

Keywords

cancer pathogenesis / chronic diseases / diabetes model / disease model / ethical considerations / experimental animal model / neurodegenerative diseases / noncommunicable diseases pain model

References

[1] Mukhopadhyay R, Nath S, Kumar D, Sahana N, Mandal S. Basics of the molecular biology: from genes to its function. Springer Protocols Handbooks/Springer Protocols. Springer; 2024: 343-374.

[2] Payne DA. Basics of molecular biology. Springer eBooks. Springer; 2016: 1-17.

[3] Lee KH, Lee DW, Kang BC. The ‘R’ principles in laboratory animal experiments. Lab Anim Res. 2020; 36(1): 45.

[4] Andersen ML, Winter LM. Animal models in biological and biomedical research—experimental and ethical concerns. An Acad Bras Cienc. 2017; 91(suppl 1):e20170238.

[5] Baptista CVJ, Faustino-Rocha AI, Oliveira PA. Animal models in pharmacology: a brief history awarding the Nobel prizes for physiology or medicine. Pharmacology. 2021; 106(7–8): 356-368.

[6] Swearengen JR. Choosing the right animal model for infectious disease research. Anim Models Exp Med. 2018; 1(2): 100-108.

[7] Domínguez-Oliva A, Hernández-Ávalos I, Martínez-Burnes J, Olmos-Hernández A, Verduzco-Mendoza A, Mota-Rojas D. The importance of animal models in biomedical research: current insights and applications. Animals. 2023; 13(7):1223.

[8] Doncheva NT, Palasca O, Yarani R, et al. Human pathways in animal models: possibilities and limitations. Nucleic Acids Res. 2021; 49(4): 1859-1871.

[9] Polis B, Samson AO. Addressing the discrepancies between animal models and human Alzheimer's disease pathology: implications for translational research. J Alzheimers Dis. 2024; 98(4): 1199-1218.

[10] Polis B, Cuda CM, Putterman C. Animal models of neuropsychiatric systemic lupus erythematosus: deciphering the complexity and guiding therapeutic development. Autoimmunity. 2024; 57(1):2330387.

[11] Lee CJ, Nam Y, Rim YA, Ju JH. Advanced animal replacement testing strategies using stem cell and organoids. Int J Stem Cells. 2025; 18(2): 107-125.

[12] Teli P, Kale V, Vaidya A. Beyond animal models: revolutionizing neurodegenerative disease modeling using 3D in vitro organoids, microfluidic chips, and bioprinting. Cell Tissue Res. 2023; 394(1): 75-91.

[13] Singh VK, Seed TM. How necessary are animal models for modern drug discovery? Expert Opin Drug Discov. 2021; 16(12): 1391-1397.

[14] Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Lab Anim Res. 2022; 38(1): 18.

[15] Patwardhan B, Mutalik G, Tillu G. Drug discovery and ayurveda. Elsevier eBooks. Elsevier; 2015: 229-258.

[16] Lorkowski J, Pokorski M. Medical records: a historical narrative. Biomedicine. 2022; 10(10):2594.

[17] Bale TL, Abel T, Akil H, et al. The critical importance of basic animal research for neuropsychiatric disorders. Neuropsychopharmacology. 2019; 44(8): 1349-1353.

[18] Juárez-Portilla C, Zepeda-Hernández RC, Sánchez-Salcedo JA, Flores-Muñoz M, López-Franco Ó, Cortés-Sol A. El uso de los animales en la investigación y en la enseñanza: lineamientos y directrices para su manejo. Rev Eduscientia Divulg Cienc Educ. 2019; 2(4): 4-19. https://www.eduscientia.com/index.php/journal/article/view/52

[19] Bi Z, Hong W, Yang J, Lu S, Peng X. Animal models for SARS-CoV-2 infection and pathology. MedComm. 2021; 2(4): 548-568.

[20] Burhans MS, Hagman DK, Kuzma JN, Schmidt KA, Kratz M. Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol. 2019; 9(1): 1-58.

[21] Li Z, Zheng W, Wang H, et al. Application of animal models in cancer research: recent progress and future prospects. Cancer Manag Res. 2021; 13: 2455-2475.

[22] Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018; 21(10): 1370-1379.

[23] Fontana F, Figueiredo P, Martins JP, Santos HA. Requirements for animal experiments: problems and challenges. Small. 2020; 17(15):e2004182.

[24] Chen J, Qu J, Lou Z, Zhu B, Kang L. Research on characteristics, development trend and funding countermeasures of biology. Bull Chin Acad Sci (Chin Ver). 2022; 37(3): 308-316.

[25] Singh VP, Pratap K, Sinha J, Desiraju K, Bahal D, Kukreti R. Critical evaluation of challenges and future use of animals in experimentation for biomedical research. Int J Immunopathol Pharmacol. 2016; 29(4): 551-561.

[26] Abrhaley A, Giday M, Hailu A. Challenges and opportunities of translating animal research into human trials in Ethiopia. BMC Med Res Methodol. 2024; 24(1): 211.

[27] Cait J, Cait A, Scott RW, Winder CB, Mason GJ. Conventional laboratory housing increases morbidity and mortality in research rodents: results of a meta-analysis. BMC Biol. 2022; 20(1): 15.

[28] Rinwa P, Eriksson M, Cotgreave I, Bäckberg M. 3R-refinement principles: elevating rodent well-being and research quality. Lab Anim Res. 2024; 40(1): 11.

[29] Berard M, Da Conceiçao H, Bedu S, Mocho J. Brakes and leverages for reducing the environmental impact of laboratory animal facilities: a case study at the Institut Pasteur. Lab Anim. 2024; 59(1): 47-57.

[30] Padget M, Sörme P, Spezia M, et al. Environmental impact, cost, and acceptability of a laboratory sustainability certification program for biomedical research in an academic medical center. J Clim Chang Health. 2024; 23:100401.

[31] Freese T, Elzinga N, Heinemann M, Lerch MM, Feringa BL. The relevance of sustainable laboratory practices. RSC Sustain. 2024; 2(5): 1300-1336.

[32] Mei J. Refining humane endpoints in mouse models of disease by systematic review and machine learning-based endpoint definition. ALTEX. 2019; 36(4): 555-571.

[33] Pakgohar A, Mehrannia H. Sample size calculation in clinical trial and animal studies. Iran J Diabetes Obes. 2024; 16(1): 42-50.

[34] Sadiq IZ, Usman A, Muhammad A, Ahmad KH. Sample size calculation in biomedical, clinical and biological sciences research. J Umm Al-Qura Univ Appl Sci. 2024; 11: 133-141.

[35] Kvastad L, Carlberg K, Larsson L, et al. The spatial RNA integrity number assay for in situ evaluation of transcriptome quality. Commun Biol. 2021; 4(1):57.

[36] Ziegenhain C, Hendriks G, Hagemann-Jensen M, Sandberg R. Molecular spikes: a gold standard for single-cell RNA counting. Nat Methods. 2022; 19(5): 560-566.

[37] Chandrasekera PC, Pippin JJ. Of rodents and men: species-specific glucose regulation and type 2 diabetes research. ALTEX. 2014; 31: 157-176.

[38] Mishra R, Upadhyay A. An update on mammalian and non-mammalian animal models for biomarker development in neurodegenerative disorders. Cell Mol Life Sci. 2025; 82(1): 147.

[39] Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Sci OA. 2015; 1(4): FSO63.

[40] Varga OE, Hansen AK, Sandøe P, Olsson I a S. Validating animal models for preclinical research: a scientific and ethical discussion. Altern Lab Anim. 2010; 38(3): 245-248.

[41] Frühwein H, Paul NW. “Lost in translation?” animal research in the era of precision medicine. J Transl Med. 2025; 23(1): 152.

[42] Marshall LJ, Bailey J, Cassotta M, Herrmann K, Pistollato F. Poor translatability of biomedical research using animals—a narrative review. Altern Lab Anim. 2023; 51(2): 102-135.

[43] Denayer T, Stöhr T, Van Roy M. Animal models in translational medicine: validation and prediction. Eur J Mol Clin Med. 2014; 2(1): 5.

[44] Voelkl B, Altman NS, Forsman A, et al. Reproducibility of animal research in light of biological variation. Nat Rev Neurosci. 2020; 21(7): 384-393.

[45] Du Sert NP, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020; 18(7):e3000410.

[46] Spanagel R. Ten points to improve reproducibility and translation of animal research. Front Behav Neurosci. 2022; 16:869511.

[47] Von Kortzfleisch VT, Karp NA, Palme R, Kaiser S, Sachser N, Richter SH. Improving reproducibility in animal research by splitting the study population into several ‘mini-experiments’. Sci Rep. 2020; 10:16579.

[48] Díaz L, Zambrano E, Flores ME, et al. Ethical considerations in animal research: the principle of 3R's. Rev Investig Clin. 2021; 73(4): 199-209.

[49] Liguori GR, Jeronimus BF, De Aquinas Liguori TT, Moreira LFP, Harmsen MC. Ethical issues in the use of animal models for tissue engineering: reflections on legal aspects, moral theory, three RS strategies, and harm–benefit analysis. Tissue Eng Part C Methods. 2017; 23(12): 850-862.

[50] Perlman RL. Mouse models of human disease: an evolutionary perspective. Evol Med Public Health. 2016; 2016(1): 170-176.

[51] Colpo GD, Ribeiro FM, Rocha NP, Teixeira AL. Animal models for the study of human neurodegenerative diseases. Elsevier eBooks. Elsevier; 2017: 1109-1129.

[52] Carmo SD, Cuello A. Modeling Alzheimer's disease in transgenic rats. Mol Neurodegener. 2013; 8(1):37.

[53] Sasaguri H, Hashimoto S, Watamura N, et al. Recent advances in the modeling of Alzheimer's disease. Front Neurosci. 2022; 16:807473.

[54] Kottaisamy CPD, Raj DS, Kumar VP, Sankaran U. Experimental animal models for diabetes and its related complications—a review. Lab Anim Res. 2021; 37(1):23.

[55] Singh R, Gholipourmalekabadi M, Shafikhani SH. Animal models for type 1 and type 2 diabetes: advantages and limitations. Front Endocrinol. 2024; 15:1359685.

[56] Rai V, Moellmer R, Agrawal DK. Clinically relevant experimental rodent models of diabetic foot ulcer. Mol Cell Biochem. 2022; 477(4): 1239-1247.

[57] Peng B, Wang Q, Luo Y, He J, Tan T, Zhu H. A novel and quick PCR-based method to genotype mice with a leptin receptor mutation (db/db mice). Acta Pharmacol Sin. 2017; 39(1): 117-123.

[58] Suriano F, Vieira-Silva S, Falony G, et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome. 2021; 9(1): 147.

[59] Berndt A, Sundberg BA, Silva KA, et al. Phenotypic characterization of the KK/HLJ inbred mouse strain. Vet Pathol. 2013; 51(4): 846-857.

[60] Khosravi-Maharlooei M, Madley R, Borsotti C, et al. Modeling human T1D-associated autoimmune processes. Mol Metab. 2021; 56:101417.

[61] Poggiogalle E, Jamshed H, Peterson CM. Circadian regulation of glucose, lipid, and energy metabolism in humans. Metabolism. 2017; 84: 11-27.

[62] Houeiss P, Boitard C, Luce S. Preclinical models to evaluate the human response to autoantigen and antigen-specific immunotherapy in human type 1 diabetes. Front Endocrinol. 2022; 13:883000.

[63] Sellers RS. Translating mouse models. Toxicol Pathol. 2016; 45(1): 134-145.

[64] Dibner C, Schibler U. Circadian timing of metabolism in animal models and humans. J Intern Med. 2015; 277(5): 513-527.

[65] Petersen KA, Zong W, Depoy LM, et al. Comparative rhythmic transcriptome profiling of human and mouse striatal subregions. Neuropsychopharmacology. 2024; 49(5): 796-805.

[66] Day C, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015; 163(1): 39-53.

[67] Tratar UL, Horvat S, Cemazar M. Transgenic mouse models in cancer research. Front Oncol. 2018; 8:268.

[68] Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018; 8(11): 1358-1365.

[69] Chuprin J, Buettner H, Seedhom MO, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023; 20(3): 192-206.

[70] Connolly KA, Fitzgerald B, Damo M, Joshi NS. Novel mouse models for cancer immunology. Annu Rev Cancer Biol. 2022; 6(1): 269-291.

[71] Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2021; 399(10319): 61-116.

[72] Takahashi Y, Fukusato T. Animal models of liver diseases. Elsevier eBooks. Elsevier; 2017: 313-339.

[73] Malečková A, Tonar Z, Mik P, et al. Animal models of liver diseases and their application in experimental surgery. Rozhl Chir. 2019; 98(3): 100-109. https://pubmed.ncbi.nlm.nih.gov/31018641/

[74] Fang T, Wang H, Pan X, Little PJ, Xu S, Weng J. Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies. Int J Biol Sci. 2022; 18(15): 5681-5697.

[75] Wu S, Wang X, Xing W, et al. An update on animal models of liver fibrosis. Front Med. 2023; 10:1160053.

[76] Zheng H, Xue H, Yun W. An overview of mouse models of hepatocellular carcinoma. Infect Agents Cancer. 2023; 18(1): 49.

[77] Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018; 392(10159): 2052-2090.

[78] Liang J, Liu Y. Animal models of kidney disease: challenges and perspectives. Kidney360. 2023; 4(10): 1479-1493.

[79] Shiva N, Sharma N, Kulkarni YA, Mulay SR, Gaikwad AB. Renal ischemia/reperfusion injury: an insight on in vitro and in vivo models. Life Sci. 2020; 256:117860.

[80] Clef NL, Verhulst A, D'Haese PC, Vervaet BA. Unilateral renal ischemia-reperfusion as a robust model for acute to chronic kidney injury in mice. PLoS One. 2016; 11(3):e0152153.

[81] Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. Am J Physiol Renal Physiol. 2018; 315(4): F1098-F1106.

[82] Adam RJ, Williams AC, Kriegel AJ. Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease. Am J Physiol Renal Physiol. 2022; 322(6): F639-F654.

[83] Leelahavanichkul A, Yan Q, Hu X, et al. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int. 2010; 78(11): 1136-1153.

[84] Gregory NS, Harris AL, Robinson CR, Dougherty PM, Fuchs PN, Sluka KA. An overview of animal models of pain: disease models and outcome measures. J Pain. 2013; 14(11): 1255-1269.

[85] Burma NE, Leduc-Pessah H, Fan CY, Trang T. Animal models of chronic pain: advances and challenges for clinical translation. J Neurosci Res. 2016; 95(6): 1242-1256.

[86] Abboud C, Duveau A, Bouali-Benazzouz R, et al. Animal models of pain: diversity and benefits. J Neurosci Methods. 2020; 348:108997.

[87] Muley MM, Krustev E, McDougall JJ. Preclinical assessment of inflammatory pain. CNS Neurosci Ther. 2015; 22(2): 88-101.

[88] Calà G, Sina B, De Coppi P, Giobbe GG, Gerli MFM. Primary human organoids models: current progress and key milestones. Front Bioeng Biotechnol. 2023; 11:1058970.

[89] Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLoS Biol. 2024; 22(6):e3002667.

[90] Guimarães AI. Are animal models necessary? Exploring (dis)advantages and alternatives. Eur J Neurosci. 2025; 61(1):e16651.

[91] Pound P. A sociological perspective on the challenges of displacing animal research within academia: the contribution of Bourdieu. NAM J. 2025; 1:100057.

[92] Festing MFW. Design and statistical methods in studies using animal models of development. ILAR J. 2006; 47(1): 5-14.

[93] Polis B, Zaknoun M, Tehawey D, Gulinello M, Putterman C. Evaluating neuropsychiatric disease in mouse models of systemic lupus erythematosus. Curr Protoc. 2025; 5(7):e70185.

[94] Strauss ME, Smith GT. Construct validity: advances in theory and methodology. Annu Rev Clin Psychol. 2008; 5(1): 1-25.

[95] Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR guiding principles for scientific data management and stewardship. Sci Data. 2016; 3:160018.

[96] Leenaars CHC, Kouwenaar C, Stafleu FR, et al. Animal to human translation: a systematic scoping review of reported concordance rates. J Transl Med. 2019; 17: 223.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.